GLP-1 & Incretin Science

The Hormone That Empties the Gallbladder, Suppressed

UKPWritten and published by UK Peptides2 min readUpdated 3 cited sources

The short answer

Cholecystokinin stimulates bile secretion and drives gallbladder contraction. Rehfeld and colleagues reported that GLP-1 suppresses cholecystokinin secretion, and framed this explicitly as the clue to the mechanism behind gallbladder adverse events with GLP-1-derived drugs.

Key facts

Key mediator
Cholecystokinin (CCK)
CCK's normal role
Bile secretion, gallbladder emptying
Effect of GLP-1
Suppresses CCK secretion
Consequence
Reduced gallbladder emptying
Mechanism paper
Rehfeld 2018 (PMID 30449207)
Related work
Gether 2019, JCEM (PMID 30137354)

What cholecystokinin does

CCK is released from the upper small intestine when fat and protein arrive. It stimulates pancreatic enzyme secretion and causes the gallbladder to contract, expelling stored bile into the intestine where it emulsifies fat. Its name is literal: cholecysto, gallbladder; kinin, to move.

Why gallbladder emptying matters

Bile stored in a gallbladder that empties infrequently becomes concentrated, and concentrated bile is closer to the point at which its cholesterol content precipitates. Stasis is the classical precondition for gallstone formation, which is why any condition reducing gallbladder emptying (prolonged fasting, intravenous feeding) raises stone risk.

Research material referenced

Retatrutide 10mg, third-party HPLC tested

Buy Retatrutide · £59.99

What Rehfeld and colleagues reported

That GLP-1 suppresses CCK secretion. Their 2018 paper in the Scandinavian Journal of Gastroenterology carries the inference in its own title, describing the finding as the clue to the mechanism of the adverse gallbladder events of GLP-1-derived drugs. The reasoning is stated in the abstract: since CCK regulates gallbladder motility and emptying, suppressing it would reduce them.

Why this is a stronger explanation than weight loss alone

Rapid weight loss is itself a recognised gallstone risk factor, so the effect could plausibly have been attributed entirely to the weight reduction these drugs produce. Identifying a specific mediator that these drugs suppress gives a second, direct pathway, and it predicts an effect that would not be explained by the magnitude of weight loss alone.

Why the two pathways are hard to separate

They act in the same participants in the same direction. Someone receiving a GLP-1 receptor agonist is simultaneously losing weight rapidly and experiencing reduced CCK-driven gallbladder emptying. This is the same attribution problem that runs through the cardiovascular and renal literature for this class: collinear exposures cannot be disentangled after the fact.

What this concerns

Licensed medicines studied in registered trials. Nothing supplied on this site is a GLP-1 receptor agonist, affects cholecystokinin, or has any bearing on gallbladder function in any person.

Frequently asked questions

How do GLP-1 drugs affect it?

Rehfeld 2018 reported that GLP-1 suppresses CCK secretion, and framed this as the clue to the mechanism behind gallbladder adverse events.

Isn't it just the weight loss?

Rapid weight loss is an independent risk factor, but the CCK finding gives a second direct pathway. The two act together and are hard to separate.

Continue researching

Related guides and reference material.

Primary sources & clinical trials

Published papers, trial registrations, regulator pages and company announcements. Links open the original.

UKP

Written and published by UK Peptides, the trading name of AURYXRESEARCH LTD (company 17388727, registered in England and Wales).

Questions or a correction? Email hello@ukpeptides.org or call +44 7426 987848.

Corrections log

More GLP-1 & Incretin Science articles

Research use only. The information above is provided for scientific and educational reference. Compounds referenced are not approved for human use and are supplied for in vitro research or reference-material purposes only. No efficacy, safety, or therapeutic claims are made.